NEW YORK (GenomeWeb News) – Galapagos said today that it has acquired the drug discovery services assets of Cambridge, UK-based Sareum Holdings for €695,000 ($1 million).
Sareum’s drug discovery services business uses x-ray crystallography to identify chemical fragments for recombination into lead compounds. The services and technology assets will be integrated into Galapagos’ BioFocus DPI unit.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.